Search Results

Alimera Sciences, Inc. today announced financial results for the first quarter of 2024.

ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc. announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved, on May 22, 2024, inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan.

Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2023.

Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it will report first quarter financial results on May 14, 2024, prior to the market open.

Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of Mr. Todd Wood as President of U.S. Operations of the Company, Mr. Elliot Maltz as Chief Financial Officer of the Company, and five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved certain inducement grants under the Alimera Sciences, Inc.